> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-27/
- Published: 2020-12-13T12:00:00.000Z
- Updated: 2026-09-14T16:39:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148296

**Notice Corrected on Drug Development Tools Guide**  
*Federal Register* notice: FDA is correcting an 11/25 notice entitled *Qualification Process for Drug Development Tools; Guidance for Industry*. The document was published with incorrect information in the Paperwork Reduction Act of 1995 section, and this notice corrects the error. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-11/pdf/2020-27288.pdf?ref=fdaweb.com). 12/11/2020

**FDA Withdraws 10 No-Longer-Marketed ANDAs**  
*Federal Register* notice: FDA is withdrawing approval of 10 ANDAs from multiple applicants after they notified the agency that the drug products were no longer marketed. The applicants also waived their opportunity for a hearing. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-11/pdf/2020-27288.pdf?ref=fdaweb.com). 12/11/2020

**Comments Extended on Electromagnetic Compatibility Guide**  
*Federal Register* notice: FDA has extended the comment period on a draft guidance entitled *Electromagnetic Compatibility of Medical Devices*. Electronic or written comments can be submitted until 2/16/2021\. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-11/pdf/2020-27350.pdf?ref=fdaweb.com). 12/11/2020

**Bone, Reproductive/Urologic Drugs Panel Renewed**  
*Federal Register* notice: FDA has announced the renewal of its Bone, Reproductive and Urologic Drugs Advisory Committee for an additional two years beyond the charter expiration date. The new charter will be in effect until 3/23/2022\. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-11/pdf/2020-27289.pdf?ref=fdaweb.com). 12/10/2020

**FDA Withdrawing Approval of Allergan’s Asacol**  
*Federal Register* notice: FDA is withdrawing the approval of an Allergan Pharmaceuticals International NDA for Asacol (mesalamine) delayed-release tablets, 400 mg. The withdrawal decision is based on FDA concerns about certain phthalate esters, including dibutyl phthalate (DBP), being developmental and reproductive toxicants in laboratory animals. Asacol (mesalamine) contains DBP as an inactive ingredient and FDA told the company in 2017 that the product presents a potential problem. Allergan has agreed to the withdrawal and waived its opportunity for a hearing. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-10/pdf/2020-27082.pdf?ref=fdaweb.com). 12/10/2020

**FDA Performance Review Board Members Announced**  
*Federal Register* notice: FDA has announced the names of the members who will serve on its fiscal year 2020 Performance Review Board. The board is intended to provide fair and impartial review of staff’s Senior Executive Service, Senior Professional, 21st Century Cures Act, and Title 42(f) performance appraisals, bonus recommendations, and pay adjustments. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-12-10/pdf/2020-27123.pdf?ref=fdaweb.com). 12/10/2020